CHANGES MONOCYTE CHEMOATTRACTANTS PROTEIN-1 IN HELICOBACTER PYLORIASSOCIATED GASTRODUODENAL DISEASES
- Authors: Matveeva L.V.1, Kapkaeva R.C.1, Chudajkin A.N.1, Mishanina L.S.1
-
Affiliations:
- National Research Mordovia State University
- Issue: Vol 8, No 2 (2018)
- Pages: 150-156
- Section: ORIGINAL ARTICLES
- Submitted: 08.09.2018
- Accepted: 08.09.2018
- Published: 08.09.2018
- URL: https://iimmun.ru/iimm/article/view/732
- DOI: https://doi.org/10.15789/2220-7619-2018-2-150-156
- ID: 732
Cite item
Full Text
Abstract
Chemoattractants monocyte protein-1 (MCP-1) is a low molecular weight cytokine, secreted by many cells of the body. The synthesis of MCP-1 can induce the lipopolysaccharides of bacteria, a range of cytokines. It is believed that MCP-1 regulates the migration and infiltration of tissue by monocytes, T-lymphocytes memory, natural killer cells, is involved in differentiation of naive T-helper cells. There is evidence oncogenic and antitumor activity of MCP-1 at different stages of tumor progression. The aim of this work was the determination and comparison of serum level of MCP-1 by infection with Helicobacter (H.) pylori in precancerous conditions and gastric cancer.
Material and methods. Surveyed with the informed consent 204 patients with precancerous diseases of the stomach, 40 patients with gastric cancer and 40 healthy volunteers. Patients at esophagogastroduodenoscopy conducted the fence of material for target biopsy for histological and microbiological studies. Blood on the immunoassay climbed in the morning on an empty stomach from the cubital vein in a volume of 5 ml in a vial without preserving agent, the serum was separated by centrifugation for 10 minutes. By ELISA in the serum of patients determined the level of MCP-1, titer of total antibodies to the cytotoxin-associated protein of H. pylori. The obtained data statistically processed.
Results. The amount of MCP-1 in serum of the patients significantly exceeded the data of healthy individuals in all groups of comparison. Values of MCP-1 during exacerbation of gastric ulcer was higher than patients with exacerbation of chronic not atrophic and focal atrophic gastritis. The concentration of MCP-1 > 280 pg/ml was detected in 17.6% of patients with pre-cancerous conditions of the stomach. When ulceration process there was a strong direct correlation of the severity of its course and the number of MCP-1 in serum. Serum level of MCP-1 in 5.0% of patients with gastric cancer was at the upper limit of normal values, and 77.5% of patients exceeded it. Indicator in gastric cancer significantly prevailed over the values in precancerous conditions, was correlated with the tumor stage. The level of MCP-1 in serum of the examined healthy volunteers, patients with exacerbation of chronic gastritis, gastric ulcer disease, polyposis, gastric cancer was correlated with the titers of total antibodies to the cytotoxin-associated protein of H. pylori.
Conclusion. Determination of serum level of MCP-1 in precancerous conditions and gastric cancer is diagnostically valuable. Comparison of indicator values with the titers of total antibodies to the cytotoxin- associated protein of H. pylori prognostically significant, as it allows to assess the intensity of the induction signal to production of a cytokine.
About the authors
L. V. Matveeva
National Research Mordovia State University
Author for correspondence.
Email: MatveevaLjubov1@mail.ru
PhD (Medicine), Associate Professor, Department of Immunology, Microbiology and Virology, Medical Institute National Research Mordovia State University, Saransk, Russian Federation
430032, Russian Federation, Saransk, Ulyanov str., 26a
Phone: +7 (8342) 35-25-16 (office). Fax: +7 (8342) 32-19-83
РоссияR. C. Kapkaeva
National Research Mordovia State University
Email: fake@neicon.ru
Graduate Student of 3 Year of Study, Department of Hospital Therapy, Medical Institute National Research Mordovia State University, Saransk, Russian Federation
РоссияA. N. Chudajkin
National Research Mordovia State University
Email: fake@neicon.ru
Graduate Student of 1 Year of Study, Department of Immunology, Microbiology and Virology, Medical Institute National Research Mordovia State University, Saransk, Russian Federation
РоссияL. S. Mishanina
National Research Mordovia State University
Email: fake@neicon.ru
Applicant, Department of Immunology, Microbiology and Virology, Medical Institute National Research Mordovia State University, Saransk, Russian Federation
РоссияReferences
- Азнабаева Л.Ф., Ганцева Х.Х., Афлятунова С.Ф. Моноцитарный хемотаксический белок в иммунопатогенезе хронической обструктивной болезни легких // Медицинская иммунология. 2011. Т. 13, № 4–5. С. 502–503. [Aznabayeva L.F., Gantseva H.H., Aflyatunova S.F. Monocyte chemotactic protein in immunopathogenesis of chronic obstructive pulmonary disease. Meditsinskaya immunologiya = Medical Immunology (Russia), 2011, vol. 13, no. 4–5, pp. 502–503. (In Russ.)]
- Бережная И.М. Роль клеток системы иммунитета в микроокружении опухоли. II. Взаимодействие клеток системы иммунитета с другими компонентами микроокружения // Онкология. 2009. Т. 11, № 2. С. 86–93. [Berezhnaya I.M. The role of cells of the immune system in the microenvironment of the tumor. II. Interaction of cells of the immunity system with other components of the microenvironment. Onkologija = Oncology, 2009, vol. 11, no. 2, pp. 86–89. (In Russ.)]
- Искакова С.С., Жармаханова Г.М., Дворацка М. Характеристика проангиогенных факторов и их патогенетическая роль // Наука и здравоохранение. 2013. № 6. С. 8–12. [Iskakova S.S., Zharmakhanova G.M., Dvoratska M. Characteristics of pro-angiogenic factors and their pathogenetic role. Nauka i zdravookhranenie = Science and Health, 2013, no. 6, pp. 8–12. (In Russ.)]
- Курусин В.М., Матвеева Л.В. Гендерные различия микробиоты желудка при заболеваниях гастродуоденальной зоны // Экспериментальная и клиническая гастроэнтерология. 2016. № 2. С. 25–29. [Kurusin V.M., Matveeva L.V. Gender features changes of microbiota gastric at diseases gastroduodenal zone. Eksperimental’naya i klinicheskaya gastroenterologiya = Experimental and Clinical Gastroenterology, 2016, vol. 126, no. 2, pp. 25–29. (In Russ.)]
- Матвеева Л.В., Мосина Л.М. Роль цитокинов семейства интерлейкина-1 в желудочном канцерогенезе. Вестник Российской академии медицинских наук. 2012. Т. 67, № 11. С. 59–65. [Matveeva L.V., Mosina L.M. The role of interleukin-1 and associated cytokines in gastric carcinogenesis. Vestnik Rossiiskoi akademii meditsinskikh nauk = Herald of the Russian Academy of Sciences, 2012, vol. 67, no. 11, pp. 59–65. doi: 10.15690/vramn.v67i11.473 (In Russ.)]
- Матвеева Л.В., Стенина М.А., Мосина Л.М. Цитокиновая регуляция ульцерогенеза слизистой оболочки гастродуоденальной зоны. Медицинская иммунология. 2013. Т. 15, № 2. С. 107–119. [Matveeva L.V., Stenina M.A., Mosina L.M. Cytokine regulation of ulcerogenesis in gastroduodenal mucosa. Meditsinskaya immunologiya = Medical Immunology (Russia), 2013, vol. 15, no. 2, pp. 107–119. doi: 10.15789/1563-0625-2013-2- 107-118 (In Russ.)]
- Никитина В.В., Захарова Н.Б. Значение МСР-1 как предиктора сосудистых нарушений // Саратовский научно-медицинский журнал. 2010. Т. 6, № 4. С. 786–790. [Nikitina V.V., Zaharova N.B. Value МСР-1 as predict vascular disturbances. Saratovskii nauchno- meditsinskii zhurnal = Saratov Journal of Medical Scientific Research, 2010, vol. 6, no. 4, pp. 786–790. (In Russ.)]
- Фрейдлин И.С., Шейкин Ю.А. Эндотелиальные клетки в качестве мишеней и продуцентов цитокинов // Медицинская иммунология. 2001. Т. 3, № 4. С. 499–514. [Freidlin I.S., Sheikin Y.A. Endothelial cells as targets and producers of cytokines. Meditsinskaya immunologiya = Medical Immunology (Russia), 2001, vol. 3, no. 4, pp. 499– 514. (In Russ.)]
- Deshmane S.L., Kremlev S., Amini S., Sawaya B.E. Monocyte chemoattractant protein-1 (MCP-1): an overview. J. Interferon. Cytokine Res., 2009, vol. 29, iss. 6, pp. 313–326. doi: 10.1089/jir.2008.0027
- Kuroda T., Kitadai Y., Tanaka S., Yang X., Mukaida N., Yoshihara M., Chayama K. Monocyte chemoattractant protein-1 transfection induces angiogenesis and tumorigenesis of gastric carcinoma in nude mice via macrophage recruitment. Clin. Cancer Res., 2005, vol. 11, no. 21, pp. 7629–7636. doi: 10.1158/1078-0432.CCR-05-0798
- Li M., Knight D.A., Snyder A.L., Smyth M.J., Stewart T.Y. A role for CCL2 in both tumor progression and immunosurveillance. Oncoimmunology, 2013, vol. 2, no. 7: e25474. doi: 10.4161/onci.25474
- Mori N., Ueda A., Geleziunas R., Wada A., Hirayama T., Yoshimura T., Yamamoto N. Induction of monocyte chemoattractant protein 1 by Helicobacter pylori involves NF-kB. Infect. Immun., 2001, vol. 69, no. 3, pp. 1280–1286. doi: 10.1128/IAI.69.3.1280-1286.2001
- Ohta M., Kitadai Y., Tanaka S., Yoshiara M., Yasui W., Micaida N., Naruma K., Chayama K. Monocyte chemoattractant protein-1 expression correlates with macrophage infiltration and tumor vascularity in human gastric carcinomas. Int. J. Oncol., 2003, vol. 22, no. 4, pp. 773–778.
- Qian B.Z., Li J., Zhang H., Kitamura T., Zhang J., Campion L.R., Kaiser E.A., Snyder L.A., Pollard J.W. CCL2 recruits inflammatory monocytes to facilitate breast tumor metastasis. Nature, 2011, vol. 475, no. 7355, pp. 222–225. doi: 10.1038/nature10138
- Shimoyama T., Everett S.M., Dixon M.F., Axon A.T., Crabtree J.E. Chemokine mRNA expression in gastric mucosa is associated with Helicobacter pylori cagA positivity and severity of gastritis. J. Clin. Pathol., 1998, vol. 51, no. 10, pp. 765–770.
- Tao L.L., Shi S.J., Chen L.B., Huang G.C. Expression of monocyte chemotactic protein-1/CCL2 in gastric cancer and its relationship with tumor hypoxia. World J. Gastroenterol., 2014, vol. 20, no. 15, pp. 4421–4427. doi: 10.3748/wjg.v20.i15.4421
- Watanabe N., Shimada T., Ohtsuka Y., Hirashi H., Terano A. Proinflammatory cytokines and Helicobacter pylori stimulate CCchemokine expression in gastric epithelial cells. J. Physiol. Pharmacol., 1997, vol. 48, no. 3, pp. 405–413.
- Zhang J., Yan Y., Cui X., Zhang J., Yang Y., Li H., Wu H., Li J., Wang L., Li M., Liu X., Wang J., Duan X. CCL2 expression correlates with Snail expression and affects the prognosis of patients with gastric cancer. Pathol. Res. Pract., 2017, vol. 213, iss. 3, pp. 217–221. doi: 10.1016/j.prp.2016.12.013